Key statistics
On Friday, Axsome Therapeutics Inc (19X:DUS) closed at 84.46, -6.76% below its 52-week high of 90.58, set on Feb 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 83.44 |
---|---|
High | 84.46 |
Low | 83.32 |
Bid | 83.82 |
Offer | 84.42 |
Previous close | 84.76 |
Average volume | 38.30 |
---|---|
Shares outstanding | 48.00m |
Free float | 39.46m |
P/E (TTM) | -- |
Market cap | 4.32bn USD |
EPS (TTM) | -6.51 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 18:30 GMT.
More ▼
Announcements
- Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
- Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
- Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
- Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
- Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
- Axsome Therapeutics to Participate in Investor Conferences in September
- Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
- Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
More ▼